Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.58 |
| ▸ | CA2 | P00918 | 13/20 | 0.58 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | CES2 | O00748 | 4/20 | 0.44 |
| ▸ | CES1 | P23141 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 10/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937442 | 0.86 | CA1 (0.50) | CA1CA2CA4CES2CES1 | |
| SCHEMBL811680 | 0.80 | POLB (0.41) | CA1CA2CA4CES2CES1 | |
| SCHEMBL3694281 | 0.80 | CA1 (0.43) | CA1CA2CA4CES2CES1 | |
| SCHEMBL28298959 | 0.77 | POLB (0.39) | CA1CA2CA4CES2CES1 | |
| SCHEMBL161645 | 0.77 | CES2 (0.42) | CA1CA2CA4CES2CES1 | |
| SCHEMBL7146004 | 0.77 | CES2 (0.46) | CA1CA2CA4CES2CES1 | |
| SCHEMBL30816046 | 0.77 | POLB (0.41) | CA1CA2CA4CES2CES1 | |
| SCHEMBL29782972 | 0.77 | CES2 (0.46) | CA1CA2CA4CES2CES1 | |
| SCHEMBL200974 | 0.77 | CA1 (0.40) | CA1CA2CA4CES2CES1 | |
| SCHEMBL9693672 | 0.76 | CA1 (0.61) | CA1CA2CA4CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-7205440-B2 | Method of producing amines | LANXESS DEUTSCHLAND GMBH (DE) | 2007-04-17 | — | — | US | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050113582-A1 | Method for producing amines | LANXESS DEUTSCHLAND GMBH (DE) | 2005-05-26 | — | — | US | claimed |
| EP-1472212-A1 | METHOD FOR PRODUCING AMINES | Bayer Chemicals AG (DE) | 2004-11-03 | — | — | EP | claimed |
| WO-2003051817-A1 | METHOD FOR PRODUCING AMINES | BAYER CHEMICALS AG (DE) | 2003-06-26 | — | — | WO | claimed |
| EP-3751336-B1 | DISPLAY SUBSTRATE AND DISPLAY DEVICE | BOE TECHNOLOGY GROUP CO LTD (CN) | 2026-05-06 | — | — | EP | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20220336543-A1 | DISPLAY SUBSTRATE AND DISPLAY DEVICE | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2022-10-20 | — | — | US | disclosed |
| US-20220328572-A1 | DISPLAY SUBSTRATE AND DISPLAY DEVICE | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2022-10-13 | — | — | US | disclosed |
| US-11462591-B2 | Display device comprising a specified arrangement of sub-pixels and spacers | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2022-10-04 | — | — | US | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050113582-A1 | Method for producing amines | LANXESS DEUTSCHLAND GMBH (DE) | 2005-05-26 | — | — | US | disclosed |
| EP-1472212-A1 | METHOD FOR PRODUCING AMINES | Bayer Chemicals AG (DE) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003051817-A1 | METHOD FOR PRODUCING AMINES | BAYER CHEMICALS AG (DE) | 2003-06-26 | — | — | WO | disclosed |
| WO-1997040007-A1 | 2,3,5,6-TETRAFLUOROBENZOIC ACID AMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997040007-A1 | 2,3,5,6-TETRAFLUOROBENZOIC ACID AMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113582-A1 | Method for producing amines | HNMT, TYR, INMT | CA1 1952/4885CA2 880/4885CA4 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.